Indication
Human Papillomavirus-Related Carcinoma
18 clinical trials
36 products
3 drugs
Clinical trial
A Multicenter Randomized, Blinded, Placebo-controlled Phase III Clinical Trial Evaluating the Protective Efficacy, Safety and Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 YearsStatus: Recruiting, Estimated PCD: 2028-06-01
Product
placeboProduct
IBRX-042Clinical trial
QUILT-3.100: Phase 1 Open-Label Study to Evaluate Safety And Determine The Maximum Tolerated Dose of IBRX-042 In Subjects With HPV-Associated Tumors.Status: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second Line or CUE-101 Combination Therapy With Pembrolizumab in First Line Patients With HPV16+ Recurrent/Metastatic HNSCCStatus: Active (not recruiting), Estimated PCD: 2024-11-01
Product
CUE-101Clinical trial
A Phase Ib/II Trial Evaluating the Combination of TG4001 and Avelumab in Patients With HPV-16 Positive Recurrent or Metastatic Malignancies.Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
AvelumabProduct
TG4001Product
PRGN-2009Clinical trial
A Randomized, Open-label, Two-arm, Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer.Status: Recruiting, Estimated PCD: 2028-01-30
Product
PembrolizumabClinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Evaluating the Efficacy, Safety, and Immunogenicity of a 14- Valent Recombinant Human Papillomavirus Vaccine (SCT1000) in Healthy Women Aged 18-45 YearsStatus: Active (not recruiting), Estimated PCD: 2024-03-01
Clinical trial
HPV-16/18 E6/E7-Specific T Lymphocytes in Patients With Relapsed HPV-Associated CancersStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Product
HPV Specific T CellsDrug
cyclophosphamideProduct
FludarabineProduct
NivolumabClinical trial
A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated CancersStatus: Recruiting, Estimated PCD: 2025-01-01
Product
E7 TCR-T cellsClinical trial
A Feasibility Study of E7 TCR-T Cell Induction Therapy for Locoregionally Advanced HPV-Associated CancersStatus: Not yet recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, a Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Product
HPV16 RG1 VLP VaccineClinical trial
Stimulating Immune Response With Neoadjuvant Human Papilloma Virus (HPV)-16 Specific Vaccination in HPV-Oropharyngeal Squamous Cell Carcinoma (HPV-OPSCC)Status: Recruiting, Estimated PCD: 2025-07-01
Drug
mFOLFOX6Clinical trial
Phase II Trial Evaluating Selective Minimal Residual Disease Directed Adjuvant Radiation in Human Papilloma Virus Associated Oropharynx CarcinomaStatus: Recruiting, Estimated PCD: 2025-03-24
Product
ChemoradiationClinical trial
Pilot Phase II Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx CancerStatus: Recruiting, Estimated PCD: 2026-07-01
Product
Platinum-based chemotherapyClinical trial
A Prospective, Single-Arm, Open-Label, Non-Randomized, Phase IIA Trial of a Nonavalent Prophylactic HPV Vaccine to Assess Immunogenicity of a Prime and Deferred-Booster Dosing Schedule Among 9-11 Year-Old Girls and BoysStatus: Active (not recruiting), Estimated PCD: 2020-02-06
Clinical trial
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants With Antigen-positive Locally Advanced (Unresectable) or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-12-30
Product
TSC-200-A0201Product
TSC-203-A0201Product
TSC-204-A0101Product
TSC-201-B0702Product
TSC-204-A0201Product
TSC-204-C0702Clinical trial
Phase 2 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2023-06-01
Product
IPI-549Product
TSC-204Clinical trial
A Randomised, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of 15-valent Human Papillomavirus Recombinant Vaccine (Hansenulapolymorpha) in Healthy Chinese People Aged 18-45 YearsStatus: Not yet recruiting, Estimated PCD: 2025-02-05
Drug
VarlilumabClinical trial
A Randomized, Double-blinded, Multicenter and Placebo-controlled Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Recombinant Vaccine (Hansenula Polymorpha) in Chinese Males Aged 18-45 YearsStatus: Not yet recruiting, Estimated PCD: 2027-07-30
Product
Keytruda